The tweet was deleted by the author.
But we saved everything 🙂.
Altimmune has announced promising 48-week topline results from their IMPACT Phase 2b trial on an investigational glucagon/GLP-1 dual receptor agonist in treating MASH. The company believes this announcement marks a significant milestone in the development of their unique dual-action therapy. Further details about this breakthrough are highlighted on their official website, showcasing the potential impact of this innovative treatment on medical options for MASH.
Altimmune’s latest clinical achievement arrives amid a period of transformation for the company, following its recent leadership change as CEO Vipin Garg stepped down—a development detailed in the context of Chairman Jerry Durso’s succession in this earlier coverage of the Altimmune leadership change. The evolving management landscape may play a pivotal role in steering the company’s strategic direction as it advances innovative therapies for metabolic diseases.